Inactive Instrument

News Nanexa AB (publ) Nasdaq Stockholm

Equities

SE0007074166

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Nanexa invites to Capital Markets Day on May 7	Apr. 29	AQ
Approval of clinical trial application for NEX-22 study delayed	Apr. 16	AQ
Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	Apr. 16	CI
Notice of annual general meeting in Nanexa AB (publ)	Apr. 15	AQ
Nanexa publishes annual report for 2023	Mar. 27	AQ
Transcript : Nanexa AB - Special Call	Mar. 07
Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized	Feb. 22	AQ
Equity Research \| NANEXA: Focus on dual GLP-1 opportunities and the partner projects	Feb. 22	AQ
Nanexa publishes year-end report and Q4 report 2023	Feb. 21	AQ
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Invitation to presentation of Nanexa's year-end report and Q4 report 2023	Feb. 20	AQ
Equity Research \| NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play	Dec. 21	AQ
Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA	Dec. 20	AQ
Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA	Dec. 20	CI
Nanexa optimizes business operations through tactical priorities	Dec. 20	AQ
Nanexa changes Certified Adviser to Carnegie Investment Bank AB (publ)	Nov. 30	AQ
Nanexa Signs Feasibility Study Contract for PharmaShell; Shares Jump	Nov. 29	MT
Nanexa signs evaluation agreement with a large global pharmaceutical company	Nov. 29	AQ
Nanexa Q3 - Focused approach	Nov. 21	AQ
Equity Research \| NANEXA: Raising our LOAs following a review of the projects	Nov. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nanexa AB (publ) Nasdaq Stockholm

Equities

SE0007074166

Summary

Filters